Mylan to supply anti-retrovirals to South African government
The Indian drug firm has bagged the tender for the two year period starting January 1, 2013 to December 31, 2014.
Hyderabad, December 1, 2012: Mylan Laboratories Ltd will soon become one of the lead suppliers of anti-retroviral (ARV) drugs to South African Department of Health. It is to be noted here that the company has bagged the contract for two years i.e. 2013-14.
The Indian subsidiary of Mylan Inc has announced that the value of the contract is Rand 1.12 billion share (Rs 700 crore) which translated into 19.1 per cent of the total tender value of Rand 5.9 billion tender value (Rs 4,000 crore).
As part of this contract, Mylan Labs will supply the South African Government with 31 per cent of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender.
“The company will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs,” said Ms Heather Bresch, Chief Executive Officer, Mylan Inc.
Mylan supplies ARV drugs to over 120 countries and close to one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product.